查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
胃食管反流藥物全球市場規模、份額、按類型分類的行業趨勢分析報告（抗酸劑、質子泵抑製劑 (PPI)、H2 受體阻滯劑、促動力藥），區域展望和預測，2022 年 2028-2028 年
市場調查報告書
商品編碼
1261357

胃食管反流藥物全球市場規模、份額、按類型分類的行業趨勢分析報告（抗酸劑、質子泵抑製劑 (PPI)、H2 受體阻滯劑、促動力藥），區域展望和預測，2022 年 2028-2028 年

Global Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Regional Outlook and Forecast, 2022 - 2028
出版日期: | 出版商: KBV Research | 英文 130 Pages | 訂單完成後即時交付

價格

在預測期內，胃食管反流病市場規模預計將以 2.2% 的複合年增長率增長，到 2028 年達到 56 億美元。

此外，患有胃酸反流的人可能會出現持續咳嗽、喉炎、喘息、灼痛或喉嚨痛、哮喘加劇以及夜間睡眠困難。 在極少數情況下，持續反流會導致狹窄、食管炎、轉化和惡性腫瘤。 下食管括約肌的內在壓力、胸膈對 LES 的外在壓迫以及希氏銳角被認為構成了抗反流屏障。 一過性 LES 鬆弛 (TLESR)、LES 低血壓和食管胃交界處 (EGJ) 的物理障礙，即食管裂孔疝，已被確定為反流的三個最常見原因。

TLESR 發生在吞嚥過程中，並允許食團從食道進入胃部，是很大一部分健康人和 GERD 患者最重要的反流機制。 還誘導了二次蠕動，它通過迷走神經反射起源於食道中段，迷走神經反射啟動主要位於下心區的胃感受器的激活。 因此，導致 TLESR 的主要因素是胃擴張，通常由胃中存在空氣或食物引起。 這解釋了為什麼 TLESR 主要是餐後事件。

COVID-19 影響分析

COVID-19 大流行對市場產生了負面影響。 自大流行開始以來，COVID-19 對人類健康的影響一直備受爭議，胃食管反流病 (GERD) 也不例外。 人們擔心病毒可能會從 GI（胃腸道）道逸出，並通過腸肺軸在其他器官系統（例如呼吸系統）中引起症狀、感染或炎症。 腸道是人體最大的免疫器官，可能含有快速生長的 COVID-19 病毒群落。 此類分析和研究表明 COVID-19 與 GERD 之間存在聯繫，這極大地阻礙了市場的增長。

市場增長因素

過度進食快餐導致消化系統紊亂

快餐中含有各種毒素和化學物質以及過量的鹽分，自然會增加腹脹、胃潰瘍甚至胃癌的機率。 當您（從快餐中）吸收更多的鹽分時，鈉會導致更多的水分滯留，從而導致胃痛、腹部腫脹和腹脹。 成年人的快餐消費隨著財富的增加而增加，隨著年齡的增長而減少。 男性和女性的快餐消費量大致相同，男性在午餐時吃得更多，而女性在兩餐之間吃得更多。 全球快餐消費的增長正在增加胃食管反流病的病例數量，推動市場的增長。

酒精消費激增

個人因素包括年齡、性別、家庭環境和社會經濟地位。 雖然沒有單一的風險因素占主導地位，但更容易出現酒精相關問題的人更有可能飲酒。 與富人相比，不太富裕的人因飲酒而面臨更多的健康和社會問題。 研究還表明，飲酒會增加胃食管反流病的風險。 飲酒量的增加可能會影響這種疾病的總體患病率，並成為胃食管反流病市場擴張的推動力。

市場約束

與胃食管反流藥物相關的副作用示例

抗酸劑會導致某些人過敏，並使他們更容易對某些食物過敏。 抗酸劑的副作用通常是由於劑量不當引起的。 一些抗酸劑含有鈣，包括 Maalox、Mylanta、Rolaids 和 Tums。 如果患者服用的劑量超過或超過推薦量，則可能會出現鈣過量。 鈣攝入過多的症狀包括噁心、嘔吐、精神狀態改變和腎結石。 鈣攝入過多也會引起鹼中毒。 在這種狀態下，身體無法產生足夠的酸來有效工作。 如果患者覺得他們需要服用大量抗酸劑才能感覺好些，則可能表明存在另一種疾病。

按類型劃分的前景

根據類型，胃食管反流藥物市場分為抗酸劑、H2 受體阻滯劑、質子泵抑製劑 (PPI) 和促動力劑。 2021 年，胃食管反流藥物市場由質子泵抑製劑 (PPI) 部分主導。 這是因為它們是最常推薦用於治療胃灼熱和缺氧相關症狀的一組藥物。 這些藥物通過抑制胃壁細胞產生酸來發揮作用。 PPI 可通過非處方藥和處方藥獲得。 奧美拉唑和蘭索拉唑是歷史最悠久、醫生和患者最為熟知的藥物。

區域展望

按地區劃分，對北美、歐洲、亞太地區和 LAMEA 的胃食管反流病市場進行了分析。 到 2021 年，北美將佔據胃食管反流病市場的最高收入份額。 這是由於社區中 GERD 發病率的增加以及 GERD 藥物使用的增加。 也有越來越多的運動來提高公眾對該問題的認識，從而增加了對 GERD 治療藥物的需求。 該活動旨在為患有 GERD 的人提供一個簡單的食譜來防止反流。

內容

第一章市場範圍與研究方法

  • 市場定義
  • 目的
  • 市場範圍
  • 細分
    • 全球胃食管反流藥物市場：按類型分類
    • 全球胃食管反流藥物市場：按地區
  • 調查方法

第 2 章市場概述

  • 介紹
    • 概覽
      • 市場構成和情景
  • 影響市場的主要因素
    • 市場驅動力
    • 市場製約因素

第 3 章全球胃食管反流藥物市場：按類型

  • 全球抗酸劑市場：按地區
  • 全球質子泵抑製劑 (PPI) 市場，按地區
  • 全球 H2 受體阻滯劑市場：按地區
  • 全球運動促進劑市場：按地區

第 4 章全球胃食管反流藥物市場：按地區

  • 北美
    • 北美市場：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
      • 其他北美地區
  • 歐洲
    • 歐洲市場：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 俄羅斯
      • 西班牙
      • 意大利
      • 其他歐洲地區
  • 亞太地區
    • 亞太市場：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 新加坡
      • 馬來西亞
      • 其他亞太地區
  • 拉丁美洲/中東/非洲
    • 按國家/地區劃分的拉丁美洲/中東/非洲市場
      • 巴西
      • 阿根廷
      • 阿拉伯聯合酋長國
      • 沙特阿拉伯
      • 南非
      • 尼日利亞
      • 其他拉丁美洲/中東/非洲地區

第五章公司簡介

  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • GlaxoSmithKline PLC（GSK）
  • Johnson & Johnson
  • Ironwood Pharmaceuticals, Inc
  • Eisai Co, Ltd.
  • Medigus Ltd
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc
  • Camber Pharmaceuticals, Inc（Hetero Labs Limited）

The Global Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 2.2% CAGR during the forecast period.

A digestive illness called gastroesophageal reflux disease (GERD) occurs when stomach contents, including acid, food, and liquids, leak into the esophagus. The lining of the esophagus is irritated, giving patients a burning feeling. Heartburn (reflux) and regurgitation are the primary esophageal symptoms defining GERD. Moreover, GERD may result in esophageal inflammation if ignored for a long time. It is linked to sleep problems and low quality of life.

Upper endoscopy, an ambulatory acid (PH) probe test, esophageal manometry, and X-rays are the primary methods used to diagnose it. Changing one's lifestyle and using regulated drugs might help manage certain conditions, but others may also need surgery or powerful medications. Burning in the chest, dysphagia, belching, epigastric discomfort, trouble swallowing, regurgitation of food or sour liquid, and a lump in the throat are typical indications and symptoms of the condition.

Moreover, acid reflux sufferers may have a persistent cough, laryngitis, wheezing, burning or painful throat sensations, increasing asthma, and sleep difficulties at night. In rare cases, persistent reflux may result in stricture, esophagitis, metaplasia, or malignancy. The lower esophageal sphincter's intrinsic pressure, the crural diaphragm's extrinsic compression of the LES, and the acute angle of His are hypothesized to make up the anti-reflux barrier. Transient LES relaxations (TLESRs), LES hypotension, and physical disruption of the esophagogastric junction (EGJ), or hiatus hernia, are the three most common causes of reflux.

TLESRs, which occur during swallows to allow the passage of a bolus from the esophagus into the stomach, are the most important mechanism of reflux in healthy subjects and a significant portion of GERD patients. They are also induced by secondary peristalsis, which starts from the mid-esophagus due to a vago-vagal reflex beginning with the activation of gastric receptors primarily located in the sub-cardiac region. As a result, the primary factor that causes a TLESR is stomach distension, often brought on by gastric air or the presence of food, which explains why TLESRs are mostly a postprandial event.

COVID-19 Impact Analysis

The COVID-19 pandemic affected the market negatively during the pandemic phase. COVID-19's effects on many aspects of human health have been extensively discussed since the start of the pandemic, and gastroesophageal reflux disease (GERD) is no exception. There was a worry that the virus may move beyond the GI (gastrointestinal) tract by generating symptoms in other organ systems, such as the respiratory system, through a gut-lung axis or by causing infection or inflammation. The gut, the body's biggest immunological organ, may be home to colonies of COVID-19 virus, which reproduces quickly. Because of the association between COVID-19 and GERD shown by such analysis and research, the market growth was hampered significantly.

Market Growth Factors

High intake of fast food causing digestive diseases

Fast food naturally raises the chance of bloating, stomach ulcers, and sometimes even stomach cancer since it includes a variety of hazardous substances, chemicals, and excessive amounts of salt. If the body absorbs more salt (from fast food), the sodium will retain more water, which may cause stomach pain and abdominal swelling or bloating. Fast food consumption among adults rose with wealth while decreasing with age. Fast food consumption was similar across men and women, with a more significant proportion of men eating it for lunch and a higher proportion of women eating it as a snack. The growing consumption of fast food globally will increase the cases of gastroesophageal reflux diseases and propel market growth.

The surging consumption of alcohol

Personal factors include age, gender, domestic circumstances, and socioeconomic status. Although no one risk factor predominates, those who are more vulnerable to alcohol-related problems are more likely to use alcohol. Less wealthy individuals have more significant health and social issues due to alcohol use than more affluent individuals. Studies have also shown that drinking alcohol increases the risk of gastroesophageal reflux disease. The growing use of alcohol will have an impact on the disease's overall prevalence and may help drive the gastroesophageal reflux diseases market expansion.

Market Restraining Factors

Some side effects associated with gastroesophageal reflux disease's medications

Antacids may cause allergies in certain persons and make it more likely for people to become allergic to certain foods. Antacid side effects are often caused by improper dosage. Several antacids include calcium, including Maalox, Mylanta, Rolaids, and Tums. A calcium overdose is possible if the patient takes them in excess or longer than recommended. Symptoms of too much calcium include nausea, vomiting, altered mental state, and kidney stones. Alkalosis may also result from too much calcium. The body can't produce enough acid in this state for it to work effectively. It might indicate another disease if the patient feels they need to take a lot of antacids to feel better.

Type Outlook

Based on type, the gastroesophageal reflux disease therapeutics market is segmented into antacids, H2 receptor blockers, proton pump inhibitors (PPIs) and pro-kinetic agents. The proton pump inhibitors (PPIs) segment acquired a significant revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is due to the fact that it is the most often recommended family of medications for treating heartburn and conditions linked to acidity. They work by inhibiting acid production in the stomach's parietal cells. Both over-the-counter and prescription PPIs are offered. Omeprazole and lansoprazole are two medications that have been around the longest and are thus the most well-known to doctors and patients.

Regional Outlook

Region-wise, the gastroesophageal reflux disease therapeutics market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the gastroesophageal reflux disease therapeutics market in 2021. This is owing to the increased incidence of GERD in the local population and the rising use of GERD therapies. Also, there are more and more campaigns to raise public awareness of the problem, driving up demand for GERD treatments. The campaign aimed to provide GERD sufferers with simple-to-follow recipes that are reflux-friendly.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

  • Antacids
  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Blockers
  • Pro-kinetic Agents

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • AstraZeneca PLC
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Medigus Ltd.
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Gastroesophageal Reflux Disease Therapeutics Market, by Type
    • 1.4.2 Global Gastroesophageal Reflux Disease Therapeutics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition & scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market by Type

  • 3.1 Global Antacids Market by Region
  • 3.2 Global Proton Pump Inhibitors (PPIs) Market by Region
  • 3.3 Global H2 Receptor Blockers Market by Region
  • 3.4 Global Pro-kinetic Agents Market by Region

Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market by Region

  • 4.1 North America Gastroesophageal Reflux Disease Therapeutics Market
    • 4.1.1 North America Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.1.1 North America Antacids Market by Country
      • 4.1.1.2 North America Proton Pump Inhibitors (PPIs) Market by Country
      • 4.1.1.3 North America H2 Receptor Blockers Market by Country
      • 4.1.1.4 North America Pro-kinetic Agents Market by Country
    • 4.1.2 North America Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.1.2.1 US Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.1.1 US Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.2 Canada Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.2.1 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.3 Mexico Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.3.1 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.1.2.4 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market
        • 4.1.2.4.1 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.2 Europe Gastroesophageal Reflux Disease Therapeutics Market
    • 4.2.1 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.1.1 Europe Antacids Market by Country
      • 4.2.1.2 Europe Proton Pump Inhibitors (PPIs) Market by Country
      • 4.2.1.3 Europe H2 Receptor Blockers Market by Country
      • 4.2.1.4 Europe Pro-kinetic Agents Market by Country
    • 4.2.2 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.2.2.1 Germany Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.1.1 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.2 UK Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.2.1 UK Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.3 France Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.3.1 France Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.4 Russia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.4.1 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.5 Spain Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.5.1 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.6 Italy Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.6.1 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.2.2.7 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market
        • 4.2.2.7.1 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.3 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
    • 4.3.1 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.1.1 Asia Pacific Antacids Market by Country
      • 4.3.1.2 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country
      • 4.3.1.3 Asia Pacific H2 Receptor Blockers Market by Country
      • 4.3.1.4 Asia Pacific Pro-kinetic Agents Market by Country
    • 4.3.2 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.3.2.1 China Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.1.1 China Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.2 Japan Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.2.1 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.3 India Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.3.1 India Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.4 South Korea Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.4.1 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.5 Singapore Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.5.1 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.6 Malaysia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.6.1 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.3.2.7 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market
        • 4.3.2.7.1 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type
  • 4.4 LAMEA Gastroesophageal Reflux Disease Therapeutics Market
    • 4.4.1 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.1.1 LAMEA Antacids Market by Country
      • 4.4.1.2 LAMEA Proton Pump Inhibitors (PPIs) Market by Country
      • 4.4.1.3 LAMEA H2 Receptor Blockers Market by Country
      • 4.4.1.4 LAMEA Pro-kinetic Agents Market by Country
    • 4.4.2 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country
      • 4.4.2.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.1.1 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.2 Argentina Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.2.1 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.3 UAE Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.3.1 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.4 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.4.1 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.5 South Africa Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.5.1 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.6 Nigeria Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.6.1 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type
      • 4.4.2.7 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market
        • 4.4.2.7.1 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type

Chapter 5. Company Profiles

  • 5.1 Takeda Pharmaceutical Company Limited
    • 5.1.1 Company Overview
    • 5.1.2 Financial Analysis
    • 5.1.3 Regional Analysis
    • 5.1.4 Research & Development Expense
  • 5.2 AstraZeneca PLC
    • 5.2.1 Company Overview
    • 5.2.2 Financial Analysis
    • 5.2.3 Regional Analysis
    • 5.2.4 Research & Development Expenses
  • 5.3 GlaxoSmithKline PLC (GSK)
    • 5.3.1 Company Overview
    • 5.3.2 Financial Analysis
    • 5.3.3 Segmental and Regional Analysis
    • 5.3.4 Research & Development Expense
  • 5.4 Johnson & Johnson
    • 5.4.1 Company Overview
    • 5.4.2 Financial Analysis
    • 5.4.3 Segmental &Regional Analysis
    • 5.4.4 Research & Development Expenses
  • 5.5 Ironwood Pharmaceuticals, Inc.
    • 5.5.1 Company Overview
    • 5.5.2 Financial Analysis
    • 5.5.3 Regional Analysis
    • 5.5.4 Research & Development Expenses
  • 5.6 Eisai Co., Ltd.
    • 5.6.1 Company Overview
    • 5.6.2 Financial Analysis
    • 5.6.3 Segmental and Regional Analysis
    • 5.6.4 Research & Development Expenses
  • 5.7 Medigus Ltd.
    • 5.7.1 Company Overview
    • 5.7.2 Financial Analysis
    • 5.7.3 Segmental and Regional Analysis
    • 5.7.4 Research & Development Expenses
  • 5.8 Sebela Pharmaceuticals
    • 5.8.1 Company Overview
    • 5.8.2 Recent strategies and developments:
      • 5.8.2.1 Partnerships, Collaborations, and Agreements:
  • 5.9 Phathom Pharmaceuticals, Inc.
    • 5.9.1 Company Overview
    • 5.9.2 Research & Development Expenses
    • 5.9.3 Recent strategies and developments:
      • 5.9.3.1 Partnerships, Collaborations, and Agreements:
  • 5.10. Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
    • 5.10.1 Company Overview
    • 5.10.2 Recent strategies and developments:
      • 5.10.2.1 Product Launches and Product Expansions:

LIST OF TABLES

  • TABLE 1 Global Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 2 Global Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 3 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 5 Global Antacids Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Antacids Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Proton Pump Inhibitors (PPIs) Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Proton Pump Inhibitors (PPIs) Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global H2 Receptor Blockers Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global H2 Receptor Blockers Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Pro-kinetic Agents Market by Region, 2018 - 2021, USD Million
  • TABLE 12 Global Pro-kinetic Agents Market by Region, 2022 - 2028, USD Million
  • TABLE 13 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2022 - 2028, USD Million
  • TABLE 15 North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 16 North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 17 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 18 North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 19 North America Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 20 North America Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 21 North America Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 22 North America Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 23 North America H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 24 North America H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 25 North America Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 26 North America Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 27 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 28 North America Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 29 US Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 30 US Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 31 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 32 US Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 33 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 34 Canada Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 35 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 36 Canada Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 37 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 38 Mexico Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 39 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 40 Mexico Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 41 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 42 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 43 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 44 Rest of North America Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 45 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 46 Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 47 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 48 Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 49 Europe Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 50 Europe Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 51 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 52 Europe Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 53 Europe H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 54 Europe H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 55 Europe Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 56 Europe Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 57 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 58 Europe Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 59 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 60 Germany Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 61 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 62 Germany Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 63 UK Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 64 UK Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 65 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 66 UK Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 67 France Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 68 France Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 69 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 70 France Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 71 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 72 Russia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 73 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 74 Russia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 75 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 76 Spain Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 77 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 78 Spain Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 79 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 80 Italy Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 81 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 82 Italy Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 83 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 84 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 85 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 86 Rest of Europe Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 87 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 88 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 89 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 90 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 91 Asia Pacific Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 92 Asia Pacific Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 93 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Asia Pacific Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Asia Pacific H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Asia Pacific H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Asia Pacific Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Asia Pacific Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 100 Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 101 China Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 102 China Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 103 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 104 China Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 105 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 106 Japan Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 107 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 108 Japan Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 109 India Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 110 India Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 111 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 112 India Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 113 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 114 South Korea Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 115 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 116 South Korea Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 117 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 118 Singapore Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 119 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 120 Singapore Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 121 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 122 Malaysia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 123 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 124 Malaysia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 125 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 126 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 127 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 128 Rest of Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 129 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 130 LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 131 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 132 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 133 LAMEA Antacids Market by Country, 2018 - 2021, USD Million
  • TABLE 134 LAMEA Antacids Market by Country, 2022 - 2028, USD Million
  • TABLE 135 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2018 - 2021, USD Million
  • TABLE 136 LAMEA Proton Pump Inhibitors (PPIs) Market by Country, 2022 - 2028, USD Million
  • TABLE 137 LAMEA H2 Receptor Blockers Market by Country, 2018 - 2021, USD Million
  • TABLE 138 LAMEA H2 Receptor Blockers Market by Country, 2022 - 2028, USD Million
  • TABLE 139 LAMEA Pro-kinetic Agents Market by Country, 2018 - 2021, USD Million
  • TABLE 140 LAMEA Pro-kinetic Agents Market by Country, 2022 - 2028, USD Million
  • TABLE 141 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2018 - 2021, USD Million
  • TABLE 142 LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Country, 2022 - 2028, USD Million
  • TABLE 143 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 144 Brazil Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 145 2023
  • TABLE 146 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 147 Brazil Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 148 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 149 Argentina Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 150 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 151 Argentina Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 152 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 153 UAE Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 154 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 155 UAE Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 156 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 157 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 158 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 159 Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 160 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 161 South Africa Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 162 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 163 South Africa Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 164 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 165 Nigeria Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 166 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 167 Nigeria Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 168 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2018 - 2021, USD Million
  • TABLE 169 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market, 2022 - 2028, USD Million
  • TABLE 170 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2021, USD Million
  • TABLE 171 Rest of LAMEA Gastroesophageal Reflux Disease Therapeutics Market by Type, 2022 - 2028, USD Million
  • TABLE 172 Key Information - Takeda Pharmaceutical Company Limited
  • TABLE 173 KEY INFORMATION - AstraZeneca PLC
  • TABLE 174 Key Information - GlaxoSmithKline PLC
  • TABLE 175 Key information -Johnson & Johnson
  • TABLE 176 Key Information - Ironwood Pharmaceuticals, Inc.
  • TABLE 177 Key Information - Eisai Co., Ltd.
  • TABLE 178 Key Information - Medigus Ltd.
  • TABLE 179 Key Information - Sebela Pharmaceuticals
  • TABLE 180 Key Information - Phathom Pharmaceuticals, Inc.
  • TABLE 181 Key Information - Camber Pharmaceuticals, Inc.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2021
  • FIG 3 Global Gastroesophageal Reflux Disease Therapeutics Market share by Type, 2028
  • FIG 4 Global Gastroesophageal Reflux Disease Therapeutics Market by Type, 2018 - 2028, USD Million
  • FIG 5 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2021
  • FIG 6 Global Gastroesophageal Reflux Disease Therapeutics Market share by Region, 2028
  • FIG 7 Global Gastroesophageal Reflux Disease Therapeutics Market by Region, 2018 - 2028, USD Million